Clinical outcomes in ER+ HER2-negative breast cancer (BC) where treatment decisions incorporated the 21-gene recurrence score (RS): Elderly (≥70 yrs) vs younger patients (Pts).Salomon M. Stemmer, David Geffen, Mariana Steiner et al.|Journal of Clinical Oncology|2017Cited by 0
Treatments/clinical outcomes in ER+ HER2-negative breast cancer (BC) where treatment decisions were recurrence score (RS)-guided: Analysis by histologic subtype.Salomon M. Stemmer, Nicky Liebermann, David Geffen et al.|Journal of Clinical Oncology|2017Cited by 0